Talk:Pyelonephritis

Medicine: Reproductive / Nephrology Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.
	This article is supported by the Reproductive medicine task force (assessed as Low-importance).
	This article is supported by the Nephrology task force (assessed as High-importance).

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Pyelonephritis.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Trimethoprim

Trimethoprim is NOT a suitable treatment for pyelonephritis. Although it works very well for cystitis when the causative bacterium is susceptible, it cannot work when the kidney is infected in cases of pyelonephritis. This is because it acts to block folic acid synthesis in bacteria. The bloodstream, which supplies the kidney, is a rich source of folic acid. Any bacteria that are present in the kidney are supplied with folic acid, overcomimg the block imposed by trimethoprim. The same is true for the combination of trimethoprim and a sulphonamide (co-trimoxazole): sulphonamides also act to block bactieral folic acid synthesis.

Micjh

Still according to PMID 10589881 it is an acceptable alternative to fluoroquinolone for susceptible organisms. --WS 20:23, 8 January 2006 (UTC)[reply]

From Trimethoprim: Bacteria are unable to take up folic acid from the environment (i.e. the infection host) thus are dependent on their own de novo synthesis - inhibition of the enzyme starves the bacteria of two bases necessary for DNA replication and transcription. So folic acid from the blood is no good for them. --WS 20:28, 8 January 2006 (UTC)[reply]

In our area we tend to use cefalosporins for pyelonephritis with systemic symptoms (e.g. fever, rigors, lassitude). With the most common cause being coliforms one could certainly make a case for trimethoprim, but rapidly progression urosepsis usually makes clinicians choose a broader spectrum, which may include ceph or fluoroquinolones. We seem to be growing a lot of trimethoprim-resistant coli strains around here these days. JFW | T@lk 21:09, 8 January 2006 (UTC)[reply]

PBC

The article suggested that PBC was a predisposing state for pyelonephritis. Searching PubMed I can only find some Japanese case reports that suggest the coliforms cause PBC through molecular mimicry, but nothing on an increase of UTIs. It bears noting that PBC is often treated with immunosuppression, and that this independently increases the risk for UTIs. JFW | T@lk 20:52, 25 July 2007 (UTC)[reply]

Descending

can also be blood born. Something about this should be added too. (utc)

Guideline

http://journals.lww.com/greenjournal/Citation/2008/03000/ACOG_Practice_Bulletin_No__91__Treatment_of.37.aspx

ACOG have issued a guideline for UTI/pyelonephritis in non-pregnant patients. Sadly, the document is not free (which is a bit silly, given that guidelines are meant to be disseminated). JFW | T@lk 22:03, 29 December 2008 (UTC)[reply]

Pyelonephritis is a SYMPTOM, not an infection.

Pyelonephritis is a description of inflammation of the renal pelvis and kidney. It is a consequence of an ascending urinary tract infection, not the infection itself. Pyelonephritis can be caused by a number of things. —Preceding unsigned comment added by 159.92.232.193 (talk) 16:16, 2 May 2011 (UTC)[reply]

It's not a symptom, but one could call it a syndrome. At the same time, it is usually caused by infection so it is not wrong to refer to it as an infection. JFW | T@lk 15:21, 5 June 2011 (UTC)[reply]

A short course in medical terminology

Collins, CE (2006). A Short Course in Medical Terminology (1st ed.). Baltimore: Lippincott Williams & Wilkins. ISBN 0781747678. Retrieved 2011-06-05.

This reference entered the article after the merge with xanthogranulomatous pyelonephritis, and DiverDave (talk · contribs) reinserted it after I took it out. I cannot see a precedent for using this as a source in any other medical articles. Occasionally we make specific references to Dorland's, but only when a definition is required and no other sources are available (e.g. in hypopituitarism). JFW | T@lk 15:21, 5 June 2011 (UTC)[reply]

Hey, Dave!

I was looking for a secondary source to replace Czaja2007, and stumbled upon the 2010 IDSA guidelines (doi:10.1093/cid/ciq257). This is an absolutely perfect source, and it can probably replace quite a few primary research studies that we are currently using. I'll be reading this over the next day or two, and hopefully do something useful with it. JFW | T@lk 06:22, 6 June 2011 (UTC)[reply]

Thanks for finding this excellent, up-to-date source which reflects a global approach to the subject. I have just finished reading it, and I see this source as being useful in replacing the inline citations for paragraph #1 of the ==Management== section. I would like to add though that IMHO the pyelonephritis article goes into far too much detail with respect to the dosing of antibiotics, coming dangerously close to giving medical advice. Seems to me it should be more general, simply stating which antibiotics are most useful under which set of circumstances. For example, we might include a statement such as:

In patients not requiring hospitalization where there is a low prevalence of antibiotic-resistant uropathogens, a once-daily oral fluoroquinolone such as ciprofloxacin or levofloxacin is an appropriate initial choice for therapy. In areas where there is a higher prevalence of fluoroquinolone resistance, a long-acting intravenous antibiotic such as ceftriaxone or an aminoglycoside is preferred.^[1]

What are your thoughts? DiverDave (talk) 01:53, 10 June 2011 (UTC)[reply]

References

^ Gupta, K (2011). "International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases" (PDF). Clinical Infectious Diseases. 52 (5): e103-20. doi:10.1093/cid/ciq257. PMID 21292654. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

πήληξ – pyelum

Eh? How can πήληξ, pḗlēx, become "pyelum"? — Preceding unsigned comment added by 83.226.139.228 (talk) 20:01, 1 January 2014 (UTC)[reply]

NEJM review

doi:10.1056/NEJMcp1702758 JFW | T@lk 13:03, 4 January 2018 (UTC)[reply]

NICE about antibiotics

https://www.nice.org.uk/guidance/NG111 JFW | T@lk 21:44, 11 June 2019 (UTC)[reply]

[Gupta2011-1] Gupta, K (2011). "International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases" (PDF). Clinical Infectious Diseases. 52 (5): e103-20. doi:10.1093/cid/ciq257. PMID 21292654. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[1]